RY 152.64 -0.722% TD 79.42 -0.3638% SHOP 86.76 0.2311% CNR 165.66 -0.2529% ENB 50.17 0.8645% CP 114.78 0.4463% BMO 119.46 0.395% TRI 223.44 -0.1118% CNQ 48.32 -1.2265% BN 63.27 -0.1263% ATD 82.05 -0.231% CSU 4214.73 0.4019% BNS 64.16 -1.1707% CM 68.67 0.0146% SU 52.85 -0.7139% TRP 56.41 2.0441% NGT 64.6 -0.9202% WCN 247.72 -0.394% MFC 35.62 -0.6138% BCE 45.62 -0.2405%

Aeterna Zentaris Inc

Healthcare CA AEZS


Last update at 2024-07-19T13:30:00Z

Day Range


52 Week Range



  • Previous Close 8.22
  • Market Cap12.77M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-15.70100M
  • Revenue TTM6.86M
  • Revenue Per Share TTM1.41
  • Gross Profit TTM 5.17M
  • Diluted EPS TTM-6.49


Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -22.72700M -8.47700M -4.72300M -6.23000M 9.64M
Minority interest - - - - -
Net income -30.19800M -8.36800M -5.11800M -6.04200M 4.19M
Selling general administrative 8.23M 5.92M 4.76M 6.62M 8.89M
Selling and marketing expenses 8.23M 1.35M 1.13M 1.21M 3.11M
Gross profit 5.48M 5.17M 1.33M 0.12M 24.78M
Reconciled depreciation 0.14M 0.14M 0.23M 0.32M 0.06M
Ebit -15.25300M -8.67100M -6.06400M -9.54400M 9.64M
Ebitda -7.64700M -8.52600M -7.90900M -9.22900M 9.70M
Depreciation and amortization 7.61M 0.14M -1.84500M 0.32M 0.06M
Non operating income net other - - - - -
Operating income -15.25300M -8.67100M -6.06400M -9.54400M 9.84M
Other operating expenses 20.89M 13.93M 9.72M 10.08M 17.04M
Interest expense 0.00300M 0.02M 3.42M 0.59M 0.00000M
Tax provision 0.00000M -0.10900M 0.40M -0.18800M 5.45M
Interest income 0.88M 0.21M 1.70M 4.61M 0.92M
Net interest income -0.00300M -0.02100M -0.73600M -0.59300M 0.28M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 7.47M -0.10900M 0.40M -0.18800M 5.45M
Total revenue 5.64M 5.26M 3.65M 0.53M 26.88M
Total operating expenses 20.74M 13.84M 7.40M 9.67M 14.94M
Cost of revenue 0.16M 0.09M 2.32M 0.41M 2.10M
Total other income expense net -7.47400M 0.19M 1.34M 3.31M -0.20300M
Discontinued operations - - - - -
Net income from continuing ops -22.72700M -8.36800M -5.11800M -6.04200M 4.19M
Net income applicable to common shares -22.72700M -8.36800M -5.11800M -6.04200M 4.19M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 56.03M 80.10M 37.28M 19.98M 25.01M
Intangible assets 0.00000M 0.62M 0.06M 0.04M 0.06M
Earning assets - - - - -
Other current assets 2.49M 1.77M 0.87M 1.21M 1.21M
Total liab 20.25M 27.12M 24.07M 22.44M 23.10M
Total stockholder equity 35.78M 52.99M 13.21M -2.46300M 1.91M
Deferred long term liab - - - - -
Other current liab 1.94M 1.89M 3.00M 2.93M 2.57M
Common stock 293.41M 293.41M 235.01M 224.53M 222.34M
Capital stock 293.41M 293.41M 235.01M 224.53M 222.34M
Retained earnings -352.08400M -334.61900M -322.65900M -316.89100M -309.78100M
Other liab - 19.32M 19.00M 16.53M 17.51M
Good will 0.00000M 8.13M 8.81M 8.05M 8.21M
Other assets 0.32M 0.34M 0.34M 0.36M 0.42M
Cash 50.61M 65.30M 24.27M 7.84M 14.51M
Cash and equivalents 0.00000M 9.70M 0.35M 7.84M 14.51M
Total current liabilities 7.04M 7.77M 5.01M 5.66M 5.60M
Current deferred revenue 2.95M 4.82M 2.19M 0.99M 0.07M
Net debt -50.43200M -65.13900M -24.08700M -6.93500M -14.51200M
Short term debt 0.11M 0.13M 0.14M 0.65M 0.00000M
Short long term debt - - - - -
Short long term debt total 0.18M 0.16M 0.18M 0.90M -
Other stockholder equity 95.42M 94.87M 101.91M 89.81M 89.34M
Property plant equipment 0.22M 0.19M 0.18M 0.62M 0.07M
Total current assets 55.49M 70.82M 27.89M 10.91M 16.26M
Long term investments - - - - -
Net tangible assets - 44.23M 4.34M -10.55300M -6.36500M
Short term investments - - - - -
Net receivables 2.16M 3.67M 1.68M 0.66M 0.29M
Long term debt - - - - -
Inventory 0.23M 0.07M 0.02M 1.20M 0.24M
Accounts payable 2.04M 0.93M 1.19M 1.09M 1.28M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.96700M -0.67800M -1.04500M 0.09M 0.01M
Additional paid in capital - - - - -
Common stock total equity - - 235.01M 224.53M 222.34M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.32M 0.34M 0.34M 0.36M 0.42M
Deferred long term asset charges - - - - -
Non current assets total 0.54M 9.28M 9.39M 9.07M 8.76M
Capital lease obligations 0.18M 0.16M 0.18M 0.90M -
Long term debt total 0.07M 0.03M 0.05M 0.26M 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.01200M -0.65800M 0.06M 0.05M -0.03500M
Change to liabilities - 3.64M 3.08M 0.13M -0.18600M
Total cashflows from investing activities -0.01200M -0.65800M 0.06M 0.05M -0.03500M
Net borrowings - -0.12700M -0.26500M -0.61400M -0.61400M
Total cash from financing activities -0.11800M 51.04M 20.47M 3.89M 3.89M
Change to operating activities - -1.09900M -1.23400M -1.04200M -1.85300M
Net income -22.72700M -8.36800M -5.11800M -6.04200M 4.19M
Change in cash -14.68900M 41.03M 16.43M -6.67400M 6.73M
Begin period cash flow 65.30M 24.27M 7.84M 14.51M 7.78M
End period cash flow 50.61M 65.30M 24.27M 7.84M 14.51M
Total cash from operating activities -13.68000M -8.58100M -4.12900M -10.72500M 6.83M
Issuance of capital stock 0.00000M 34.20M 23.50M 4.99M 0.00000M
Depreciation 0.14M 0.14M 0.23M 0.32M 0.06M
Other cashflows from investing activities -0.00100M -0.02000M 0.05M 0.05M -0.05000M
Dividends paid - - - - -
Change to inventory -0.16100M -0.05600M 1.18M -0.97100M 0.31M
Change to account receivables - 0.12M -1.33000M -0.72900M -0.09500M
Sale purchase of stock 0.00000M 54.29M 23.50M 5.30M 0.00000M
Other cashflows from financing activities 0.02M 16.96M -2.76700M -0.48100M -0.03500M
Change to netincome - -2.85800M -2.37700M -3.10400M 2.73M
Capital expenditures 0.01M 0.64M 0.03M 0.03M 0.00900M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.60M 2.50M 2.40M -2.44400M -0.15100M
Stock based compensation 0.54M 0.31M 0.06M 0.79M 0.57M
Other non cash items 7.76M -3.16900M -1.70600M -3.34700M -1.31800M
Free cash flow -13.69100M -9.22000M -4.12900M -10.72500M 6.82M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Aeterna Zentaris Inc
-0.21 2.55% 8.01 - - 1.86 0.36 0.20 1.71
Fennec Pharmaceuticals Inc
-0.02 0.23% 8.84 - 33.33 29.10 84.57 30.47 -23.3985
Sernova Corp
- -% 0.28 - - - 7.95 -4.4095
Eupraxia Pharmaceuticals Inc
0.04 1.18% 3.43 - - - 8.40 -3.9163
Theratechnologies Inc.
0.07 3.37% 2.15 - 55.25 1.64 19.46 2.23 -11.7353

Reports Covered

Stock Research & News


Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

Aeterna Zentaris Inc

315 Sigma Drive, Summerville, SC, United States, 29486

Key Executives

Name Title Year Born
Dr. Klaus Paulini Ph.D. Pres, CEO & Exec. Director NA
Dr. Nicola Ammer M.D. Chief Medical Officer & Sr. VP of Clinical Devel. NA
Dr. Matthias Gerlach Sr. VP Manufacturing & Supply Chain NA
Mr. Giuliano La Fratta Sr. VP of Fin. & CFO NA
Dr. Michael Teifel Sr. VP of Non-Clinical Devel. & Chief Scientific Officer NA
Dr. Eckhard G. Guenther Ph.D. Sr. VP of Bus. Devel. & Alliance Management and MD of AEZS Germany NA
Ms. Amélie Métivier Assistant Sec. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.